PHARMACYTE BIOTECH, INC. (PMCB) Overview
- 1 May 2026: Period ending 31 Jul 2026; Estimate (m); Actual -0.54; Beat / miss (m).
- 1 Nov 2025: Period ending 31 Jan 2026; Estimate (m); Actual -0.17; Beat / miss (m).
- 1 Aug 2025: Period ending 31 Oct 2025; Estimate (m); Actual -1.24; Beat / miss (m).
- 1 May 2025: Period ending 31 Jul 2025; Estimate (m); Actual -1.23; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $0.36
- Previous close
- $0.42
- Change
- -$0.06
- Change (%)
- -13.58%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- PMCB
- -41.83%
- S&P 500
- (m)
1 year
- PMCB
- -57.26%
- S&P 500
- (m)
3 years
- PMCB
- -80.05%
- S&P 500
- (m)
5 years
- PMCB
- -86.13%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
31 Jul 2026 ○ Estimate (m) ● Actual -0.54
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 May 2026 | 31 Jul 2026 | (m) | -0.54 | (m) | (m) |
| 1 Nov 2025 | 31 Jan 2026 | (m) | -0.17 | (m) | (m) |
| 1 Aug 2025 | 31 Oct 2025 | (m) | -1.24 | (m) | (m) |
| 1 May 2025 | 31 Jul 2025 | (m) | -1.23 | (m) | (m) |
| 1 Nov 2024 | 31 Jan 2025 | (m) | -0.44 | (m) | (m) |
30 Apr 2026 ○ Estimate (m) ● Actual -2.77
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 May 2025 | 30 Apr 2026 | (m) | -2.77 | (m) | (m) |
| 1 May 2024 | 30 Apr 2025 | (m) | 3.19 | (m) | (m) |
| 1 May 2023 | 30 Apr 2024 | (m) | -1.80 | (m) | (m) |
| 1 May 2022 | 30 Apr 2023 | (m) | -0.22 | (m) | (m) |
| 1 May 2021 | 30 Apr 2022 | (m) | -0.27 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
31 Jul 2026 ■ Revenue 0.00M ■ Earnings -5.08M — Profit margin (m)
30 Apr 2026 ■ Revenue 0.00M ■ Earnings -19.42M — Profit margin (m)
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $0.36 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning PMCB
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 31 Jul 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-16.15M
- Profit margin
- (m)
- Return on assets · 12 month
- -39.47%
- Stock compensation expense · all employees · 12 months
- (m)
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- (m)
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 402.42K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -8.61%*
- Total return · month
- -18.64%*
- Total return · quarter
- -42.62%*
- Total return · half year
- -41.01%*
- Total return · year to date
- -41.83%*
- Total return · 1 year
- -57.26%*
- Total return · 3 years
- -80.05%*
- Total return · 5 years
- -86.13%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- $0.00
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Payables · latest quarter (USD)
- $390.54K
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
PHARMACYTE BIOTECH, INC. Overview
View more →(m)
(m)
- SEC CIK
- 1157075
- Industry (SIC)
- 2836 Biological Products, (No Diagnostic Substances)
- Country of operation
- United States
- Business address
- 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS, Nevada, 89169, United States
- Fiscal year end
- 0430
- Phone
- (917) 595.2850
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |